Clinical Success for CNS mAbs Depends on More Than Mechanisms of Action Alone

The advent of monoclonal antibodies (mAbs) has transformed neurologic healthcare, improving outcomes across a wide range of diseases, from multiple sclerosis (MS) and migraine to neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG), and early-stage Alzheimer disease (eAD). What was once an ambitious, experimental goal has become a daily clinical priority.

The transition to routine implementation of mAb-based therapies for central nervous system (CNS) disorders has demonstrated that real-world success is defined less by their mechanisms of action and more by the rigorous clinical operational protocols and safety governance surrounding them. CNS mAbs introduce unique risks to patient safety, and effective development and implementation depends on sponsors and clinicians successfully navigating a set of operational considerations, including patient stratification, mandatory pre-therapy screening, and embedding critical safety rules directly into clinical infrastructure, often determining real-world success more than molecular innovation itself.

Pre-therapy screening and patient stratification

Patient safety begins long before the first infusion or injection of a CNS mAb is administered. Indication-specific safety planning that precisely aligns delivery protocols with a therapy's risk profile is a crucial first step. In managing MS with anti-CD20 therapies, such as ocrelizumab, ofatumumab, and ublituximab, safety protocols require stringent pre-treatment hepatitis B virus (HBV) screening, including testing for hepatitis B surface antigen and anti-HBV antibodies, to prevent viral reactivation.^1,2,3 Additionally, quantitative serum immunoglobulin (Ig) baselines must be established prior to the first dose to actively monitor for hypogammaglobulinemia over the course of therapy.

Similarly, the treatment of NMOSD using highly targeted therapies requires precise patient stratification based on anti-aquaporin 4 (AQP4) antibody status to ensure the therapeutic mechanism matches the specific pathophysiology of the individual.⁴ For example, in AQP4-positive patients receiving complement inhibitors such as eculizumab or ravulizumab, formation of the membrane attack complex is severely impaired, leaving patients highly susceptible to encapsulated bacteria.^5,6 To combat this, mandatory pre-initiation meningococcal vaccination, along with the potential for antibiotic prophylaxis if vaccination is delayed, is an absolute requirement for patient safety.

In another example, the approval of anti-amyloid therapies to treat eAD, such as lecanemab and donanemab, represents a modern inflection point in CNS mAb therapies. Treatment eligibility requires strict discipline in confirming the presence of amyloid pathology and conducting apolipoprotein E ε4 genotyping to assess risk, ensuring therapies are directed toward patients with the confirmed underlying pathology.⁷

Maintaining clinical vigilance

Once therapy is initiated, clinical monitoring must be well structured to ensure the timely detection of adverse events and early signs of disease relapse. The foundational era of neurologic mAbs in MS illustrates this principle. Natalizumab provided dramatic efficacy but introduced the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral brain infection that often leads to death or severe disability.⁸ To mitigate this danger, rigorous patient monitoring protocols were established, including the ongoing evaluation of anti-John Cunningham virus antibody status, treatment duration tracking, and routine magnetic resonance imaging (MRI) to detect early signs of PML.⁸

The lessons learned from MS monitoring have informed safety practices in other CNS therapies. By necessity, imaging-based vigilance has evolved into an "MRI [magnetic resonance imaging] metronome" in modern Alzheimer's disease management. For patients receiving anti-amyloid therapies, safety monitoring requires rigid adherence to routine MRI schedules prior to, and during, treatment to detect amyloid-related imaging abnormalities (ARIA), which can manifest as dangerous brain edema or hemorrhage.⁹ If clinics fall behind on ARIA monitoring or documentation, patient safety is severely compromised.

For other neurologic conditions, monitoring relies heavily on continuous laboratory and clinical assessments. NMOSD patients on interleukin-6 receptor blockers, such as satralizumab, require ongoing liver function tests and neutropenia surveillance.⁴ Patients on anti-CD19 therapies must have their baseline and periodic Ig levels tracked to actively manage infection risk.⁴ In gMG, the use of neonatal Fc receptor blockers, such as rozanolixizumab, requires clinicians to track the lowest point of total serum IgG levels and aggressively monitor for potential rebound effects or symptom fluctuations that may occur between treatment cycles.¹⁰

Embedding safety rules into clinical infrastructure

To adequately protect patient safety, clinical practices cannot rely on policy binders alone but must also embed risk management rules directly into their clinical infrastructure. Electronic order sets within electronic health records (EHRs) are crucial to operationalizing safety protocols for CNS mAb treatments and must include automated hold and restart rules tailored to specific therapies. For example, the presence of active infections must trigger an immediate hold in therapies, such as inebilizumab, ublituxima,b or ofatumumab, until the infection fully resolves. Similarly, clinical platforms should explicitly flag vaccination contraindications, automatically reminding clinicians that live-attenuated vaccines are generally not recommended during anti-CD20 treatment until complete B-cell recovery has occurred.

Accurate nomenclature is another fundamental driver of safety governance that must be embedded into the healthcare information technology infrastructure. Since 2017, FDA has required a unique four-letter suffix attached to the core nonproprietary name of biological products (e.g., ublituximab-xiiy) to support modern pharmacovigilance.¹¹ This suffix uniquely identifies the specific formulation and manufacturer, which is especially vital in the era of biosimilars. Safely governing these therapies requires recording the full non-proprietary name in EHRs. This practice prevents unintentional switching between a reference product and a biosimilar without prescriber knowledge, which could fracture safety data and complicate accurate attribution of adverse events.

Additionally, compliance with regulatory and payer mandates is non-negotiable for operationalizing safety protocols for CNS mAbs. In eAD, for example, coverage under the Centers for Medicare & Medicaid Services for anti-amyloid AD therapies is strictly contingent upon patient participation in real-world evidence registries, meaning registry fields must be actively queued in the clinical workflow before the very first dose is administered.^7,12 High-risk drugs also frequently carry Risk Evaluation and Mitigation Strategy (REMS) obligations, such as the TOUCH Prescribing Program for natalizumab or the Ultomiris ((ravulizumab-cwvz) and Soliris (eculizumab) REMS for complement inhibitors, which legally mandate specific prescriber certifications, pharmacy protocols, and documented patient counselling regarding infection risks.^5,6,8

Future horizons and the developer's mandate

As the therapeutic field rapidly advances toward next-generation solutions, such as blood-brain barrier (BBB) shuttles and engineered bispecific antibodies, the demand for meticulous safety planning are expected to intensify. Investigational dual-target therapies, such as trontinemab, utilize a molecular shuttle to cross the BBB via the endogenous transferrin pathway, offering the potential to clear amyloid plaques deeply and rapidly.¹³ Early studies indicate this approach drastically reduces the incidence of ARIA edema to less than 5%.^14,15 These innovations suggest that future technologies may decouple robust therapeutic efficacy from the severe inflammatory side effects typically associated with high-dose biologics.

For developers of these next-generation treatments, achieving clinical success requires deploying robust, scalable, and fully compliant operational protocols from the first day of launch. Developers must utilize pharmacokinetic modeling to pre-specify exposure-response relationships, build indication-specific safety surveillance networks, and thoroughly map REMS requirements long before regulatory approval is granted.

The clinical reality of modern neurologic mAbs is a strict dual mandate. It is no longer sufficient to merely develop a scientifically sound biologic. Developers and clinicians must collaboratively ensure that daily clinical practice is equipped with the precise eligibility checklists, rigid monitoring cadences, site capacity planning, and automated infrastructure rules necessary to deliver these therapies safely and effectively to the patients who need them most.

References

1. Ocrevus (ocrelizumab). Prescribing information. FDA; 2024. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761053s034lbl.pdf
2. Kesimpta (ofatumumab). Prescribing information. FDA; 2024. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125326s079lbl.pdf
3. Briumvi (ublituximab-xiiy). Prescribing information. FDA; 2022. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf
4. Center for Drug Evaluation and Research. Application number 761142Orig1s000: summary review. FDA. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761142Orig1s000SumR.pdf
5. Soliris (eculizumab). Prescribing information. FDA; 2025. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125166s448,761108s038lbl.pdf
6. Ultomiris (ravulizumab-cwvz). Prescribing information. FDA; 2022. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761108s023lbl.pdf
7. Centers for Medicare & Medicaid Services. National coverage determination: monoclonal antibodies directed against amyloid for the treatment of Alzheimer disease (NCD 200.3). Updated 2023. Accessed March 13, 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=375
8. Tysabri (natalizumab). Prescribing information. FDA; 2025. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125104s984lbl.pdf
9. FDA. FDA converts novel Alzheimer disease treatment to traditional approval. Published July 6, 2023. Accessed March 13, 2026. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
10. Center for Drug Evaluation and Research. Application number 761286Orig1s000: integrated review. FDA. Accessed March 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761286Orig1s000IntegratedR.pdf
11. FDA. Nonproprietary naming of biological products: update. Guidance for industry. Published 2020. Accessed March 13, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-update-guidance-industry
12. Palmetto GBA. Jurisdiction J Part B: drugs and biologicals. Updated 2026. Accessed March 23, 2026. https://palmettogba.com/jjb/did/a7g2dvzb39~specialties~drugs%20and%20biologicals
13. Grimm HP, Schumacher V, Schäfer M, et al. Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs. 2023;15(1):2261509. doi:10.1080/19420862.2023.2261509
14. Roche. Roche presents new insights in Alzheimer disease research across its diagnostics and pharmaceutical portfolios at AAIC. Published July 28, 2025. Accessed March 23, 2026. https://www.roche.com/media/releases/med-cor-2025-07-28
15. Genentech. Genentech and Roche present new insights in Alzheimer disease research across its diagnostics and pharmaceutical portfolios at AAIC. Published July 27, 2025. Accessed March 23, 2026. https://www.gene.com/media/press-releases/15072/2025-07-27/genentech-and-roche-present-new-insights

About the author

Bill Holt, DO, Vice President, Neuroscience Therapeutic Area, ICON

Dr Holt is a neurologist, board certified in psychiatry and neurology with sub-specialty certification in both vascular neurology and neurorehabilitation. Prior to joining ICON, he was CEO at Neurostudies, a research center focused on neuroscience clinical trials. In his current role, Dr Holt is responsible for the strategic review of protocols to provide recommendations regarding choice of subject population, endpoints, inclusion/exclusion criteria, and consultation with sponsors in development of clinical trial programs.